Drug Database
SI
sitagliptin phosphate + ipragliflozin L-proline (Sujanu / MK0431J)
✓ ApprovedKotobuki Pharmaceutical Co., Ltd. · DPP4 · Small Molecule
What is sitagliptin phosphate + ipragliflozin L-proline?
sitagliptin phosphate + ipragliflozin L-proline is a small molecule developed by Kotobuki Pharmaceutical Co., Ltd.. It is approved for therapeutic indications via oral (po).
Drug Profile
| Brand Names | Sujanu, MK0431J |
| Company | Kotobuki Pharmaceutical Co., Ltd. |
| Drug Class | Small Molecule |
| Molecular Target | DPP4, SLC5A2 |
| Route | Oral (PO) |
| Status | Approved |
Mechanism of Action
Molecular Targets
sitagliptin phosphate + ipragliflozin L-proline acts on 2 molecular targets:
| DPP4 | dipeptidyl peptidase 4 (CD26, DPPIV) |
| SLC5A2 | solute carrier family 5 member 2 (SGLT2) |
Want deeper analysis?Noah AI can explain complex mechanisms and compare to similar drugs.
Therapeutic Indications
sitagliptin phosphate + ipragliflozin L-proline is developed for 1 unique indication across 1 therapeutic area.
| Therapeutic Area | Condition | Phase |
|---|---|---|
| Metabolism and nutrition disorders | Type 2 diabetes mellitus | ✓ Approved |
Related Research Articles
Unable to load articles right now.